Clinical trial NCT05362149: An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
Official title: DEAR: Use of Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-metastatic Castration-resistant Prostate Cancer
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2022-05-05
Enrollment: 870
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult men diagnosed with nmCRPC previously untreated with a NAH agent, and starting the first treatment with a SGARI agent in United States community urology practices from August 1st, 2019 to September 30th, 2021.

Brief summary: This is an observational study in which patient data from the past on men with non-metastatic castration-resistant prostate cancer are studied. In observational studies, only observations are made without specified advice or interventions.

Non-metastatic castration-resistant prostate cancer (nmCRPC) is a type of cancer of the prostate that has not yet spread to other parts of the body, but that no longer responds adequately to initial hormone therapy/androgen deprivation therapy (ADT).

Androgens are male sex hormones such as testosterone. As they stimulate the growth of prostate cancer cells, low androgen levels are needed to reduce or slow the growth of these tumors. To reduce androgen levels in prostate cancer patients, the testes are removed through surgery or radiotherapy and subsequently androgen deprivation therapy (ADT) is started.

In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant). This worsening is called "biochemical progression" as there is an increase in the blood level of cancer biomarkers, such as prostate specific antigen \[PSA\] without detectable disease.

PSA is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development. Men with nmCRPC usually have higher levels of PSA than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body.

Second generation androgen receptor inhibitors (SGARIs) including Darolutamide, Apalutamide, and Enzalutamide are available for the treatment of nmCRPC in addition to ADT. SGARIs work by blocking androgens from attaching to proteins in cancer cells in the prostate.

It is already known that men with nmCRPC benefit from these treatments, but as men with nmCRPC commonly have no symptoms, an important therapeutic goal is to minimize side effects which can impact the patients' quality of life and potentially lead to the patient stop the treatment.

Comparative studies using data from the same database to show how treatment with Darolutamide, Apalutamide, and Enzalutamide differ from each other, are missing. In addition, there are only limited information regarding using Darolutamide, Apalutamide, and Enzalutamide in real-world settings.

In this study data are collected from the same database to learn how Darolutamide, Enzalutamide and Apalutamide are used and how safe they are under real world conditions in men with nmCRPC, who had not been treated before with SGARI or another drug called abiraterone.

The main purpose is to learn to what extent SGARI treatments are taken as prescribed. To find this out, the researchers will count the number of participants who have stopped their treatment with Darolutamide, Enzalutamide or Apalutamide at or before:

* 6 months
* 12 months
* 18 months of treatment in usual practice. In addition, characteristics of each participant group and the reason for discontinuation (stopping the treatment) will be collected and described.

The researchers will also collect any medical problems during treatment and up to 30 days after stopping the treatment and that may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AE).

The data for this study will come from the US urology EMR ( Electronic Medical Record) database.

This study will include all US patients identified in the Precision Point Specialty (PPS) urology electronic medical record (EMR) database between August 1, 2019 and September 30, 2021. The researchers will collect data from each patient for a minimum of 6 months after initiation of the SGARI treatment and up to the end of the study (March 31, 2022) or latest data cut available at the start of data extraction.

There are no required visits in this study and treatment will not be influenced.


Eligibility criteria: Inclusion Criteria:

* Men diagnosed with prostate cancer
* Diagnosis of castration-resistant prostate cancer (CRPC) prior to or during the patient identification period
* Treatment with daro, enza, or apa initiated for the first time during the patient identification period for nmCRPC
* Age ≥ 18 years at index date
* At least 6 months of electronic medical records (EMR) activity after the index date unless the patient died earlier than 6 months

Exclusion Criteria:

* Evidence of metastatic disease before or 30 days after index date.
* Prior history (within five years before index date) of other primary cancers, except for non-melanoma skin cancer
* Patients with multiple SGARIs recorded at index date
* Use of a NAH agent (daro, enza, apa or abiraterone acetate) prior to the index date
* Evidence of inclusion in clinical trials during the study period.

Primary outcomes:
measure: Composite event of treatment discontinuation/progression
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
Secondary outcomes:
measure: Time to Composite event of discontinuation/progression
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Treatment Discontinuation (non-composite event) of index treatment
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Time to treatment discontinuation (days) (non-composite event) of each treatment cohort
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Reason for discontinuation of each treatment cohort
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Proportion of patients switching to another SGARI therapy of each treatment cohort
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Dose changes during the follow-up period of each treatment cohort
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Dose intensity during the follow-up period of each treatment cohort
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
measure: Frequency of all types of AEs of each treatment cohort
timeFrame: Retrospective analysis from 01-Aug-2019 to 31-Mar-2022
Other outcomes:
Locations:
city: Whippany
country: United States
facility: Bayer
state: New Jersey
Study officials:
References: